Emergent BioSolutions (NYSE: EBS) SVP sells 4,000 shares

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Emergent BioSolutions Inc. senior vice president of Products Business Paul Anthony Williams reported an open-market sale of Common Stock. On April 1, 2026, he sold 4,000 shares at a weighted average price of $8.44 per share. The trades occurred within a price range of $8.34 to $8.54 and were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on November 14, 2025. Following this sale, Williams directly holds 62,681 shares of Emergent BioSolutions common stock.

Insider Trade Summary 10b5-1

Net Seller: 4,000 shares ($33,760)

Net Sell 1 txn

Insider Williams Paul Anthony

Role SVP, Products Business

Sold 4,000 shs ($34K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,000	$8.44	$34K

Holdings After Transaction: Common Stock — 62,681 shares (Direct)

Footnotes (1)

All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.34 to $8.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Key Figures

Shares sold: 4,000 shares Weighted average sale price: $8.44 per share Post-transaction holdings: 62,681 shares +2 more

5 metrics

Shares sold 4,000 shares Open-market sale on April 1, 2026

Weighted average sale price $8.44 per share Common Stock sale on April 1, 2026

Post-transaction holdings 62,681 shares Shares beneficially owned after April 1, 2026 sale

Sale price range $8.34–$8.54 per share Multiple trades comprising the 4,000-share sale

Trading plan adoption date November 14, 2025 Rule 10b5-1(c) trading plan governing the sale

Key Terms

Rule 10b5-1(c), weighted average price, open-market sale, Common Stock

4 terms

Rule 10b5-1(c) regulatory

"intended to comply with Rule 10b5-1(c) under the Securities Exchange Act"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

04/03/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Paul Anthony

(Last)

(First)

(Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG

MARYLAND

20879

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Products Business

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/01/2026		S		4,000⁽¹⁾	D	$8.44⁽²⁾	62,681	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.34 to $8.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Emergent BioSolutions (EBS) report for Paul Anthony Williams?

Emergent BioSolutions reported that SVP, Products Business Paul Anthony Williams sold 4,000 shares of Common Stock. The transaction was an open-market sale executed on April 1, 2026, and was disclosed in a Form 4 insider trading report filed with regulators.

How many Emergent BioSolutions (EBS) shares did the SVP sell and at what price?

Paul Anthony Williams sold 4,000 shares of Emergent BioSolutions Common Stock. The Form 4 states a weighted average sale price of $8.44 per share, with individual trades executed in a range from $8.34 to $8.54, inclusive, on April 1, 2026.

Does the Emergent BioSolutions (EBS) Form 4 indicate a Rule 10b5-1 trading plan?

Yes. The Form 4 notes that all reported transactions were made under a trading plan adopted on November 14, 2025. This plan is intended to comply with Rule 10b5-1(c), allowing pre-arranged trades that are executed automatically according to predetermined instructions.

How many Emergent BioSolutions (EBS) shares does Paul Anthony Williams hold after the sale?

After the April 1, 2026 open-market sale, Paul Anthony Williams directly holds 62,681 shares of Emergent BioSolutions Common Stock. This post-transaction ownership figure is reported in the Form 4 as the total number of shares beneficially owned following the transaction.

What role does Paul Anthony Williams hold at Emergent BioSolutions (EBS)?

Paul Anthony Williams is identified as an officer of Emergent BioSolutions, serving as Senior Vice President, Products Business. This officer title appears in the Form 4’s reporting person information and clarifies his executive leadership position within the company.

Was the Emergent BioSolutions (EBS) insider sale a direct or indirect holding transaction?

The Form 4 classifies the transaction as involving directly held shares. The ownership code is reported as “D” for direct ownership, and no nature-of-ownership footnote shifts voting or investment authority to another entity or person.